Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Weekly Oral Risperidone (LYN-005) in Schizophrenia
NCT04567524Phase 2Completed
- Sponsor
- Lyndra Therapeutics
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LYN-005 in schizophrenia and schizoaffective disorder, sponsored by Lyndra Therapeutics. Primary endpoints: Participants With at Least One Treatment Emergent Adverse Event at 35 days, Total Number of Treatment Emergent Adverse Events at 35 days and 3 more. Started Aug 2020; status: completed.
02
Drugs
LYN-005
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04567524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567524.